ClinicalTrials.gg
TerminatedNCT05066230GLOWUpdated Sep 5, 2024Results posted

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

A Phase 3 interventional study of KSI-301 and Sham injection in Non-proliferative Diabetic Retinopathy, sponsored by Kodiak Sciences Inc. Terminated at 61 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Kodiak Sciences Inc · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
All patients completed the primary endpoint assessments. Additional follow-up after the primary endpoint was deemed not necessary by the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
55th of 196
253 · median 72
Started
2021
with 17 others
Phase 3
31 of 267
4 open now
Registered
193rd of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 55th largest by enrollment of the 196 interventional ones that give a count, is one of 18 that started in 2021, is one of 31 in phase 3, and was the 193rd registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

Read the detailed description

This is a Phase 3, prospective, randomized, double-masked, sham-controlled, two-arm, multicenter study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

The primary endpoint will be assessed at Week 48; additional secondary endpoints for efficacy will be assessed at Week 48, Week 96 and if applicable, over time.

03

Conditions studied

  • Non-proliferative Diabetic Retinopathy

Keywords

  • Non-proliferative Diabetic Retinopathy
  • Diabetic Retinopathy
  • NPDR
  • KSI-301
  • VEGF
  • Anti-VEGF
  • Vascular Endothelial Growth Factor
  • Antibody Biopolymer Conjugate
  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases
  • Retinopathy
  • Vision Disorders
  • Kodiak
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to participation in the study.
  • Type 1 or 2 diabetes mellitus
  • Moderately severe to severe NPDR in the Study Eye (DRSS levels 47 and 53 as determined by the reading center), in which pan-retinal photocoagulation (PRP) can be safely deferred for at least 6 months per the Investigator.
  • BCVA ETDRS letter score in the Study Eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)
  • of ≤12%.
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Presence of center-involved DME in the Study Eye
  • Prior PRP in the Study Eye.
  • Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional retinal detachment in the Study Eye.
  • Prior intravitreal anti-VEGF treatment in the Study Eye for DR or DME.
  • Prior intravitreal or periocular in the Study Eye for DR or DME.
  • Prior use of an intravitreal treatment for DR or DME in the Study Eye.
  • Any history or evidence of a concurrent ocular condition present in the Study Eye, that in the opinion of the Investigator could require either medical or surgical intervention or alter visual acuity during the study
  • Active or suspected ocular or periocular infection or inflammation.
  • Women who are pregnant or lactating or intending to become pregnant during the study.
  • History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product.
  • Recent history (within the 6 months prior to screening) of myocardial infarction, stroke, , acute congestive heart failure or any acute coronary event.
  • Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value ≥ 100 mmHg while at rest.
  • Other protocol-specified exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    KSI-301 - Treatment Group A

    Intravitreal injection of KSI-301 (5 mg): three initiating doses, and then every 24 weeks through Week 92

    Drug: KSI-301

  • Sham comparator
    Treatment Group B

    Sham injection on the same schedule as Treatment Group A

    Other: Sham injection

Interventions

  • DrugTarcocimab tedromerStudies of Tarcocimab tedromerTarcocimab tedromer pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravitreal injection

  • OtherSham injection

    The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Improving ≥2 Steps on DRSS

    Percentage of patients improving ≥2 steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).

    Time frame: Day 1 to Week 48

Secondary outcomes

  1. Percentage of Patients Developing Any Sight-Threatening Complication

    Percentage of patients developing any of the following Sight-Threatening Complication: Proliferative Diabetic Retinopathy (PDR), Anterior segment neovascularization (ASNV), Vitreous hemorrhage or tractional retinal detachment believed to be due to PDR, or Diabetic Macular Edema (DME) from baseline through Week 48

    Time frame: Day 1 to Week 48

  2. Percentage of Patients Improving ≥3 Steps on DRSS

    Percentage of patients improving ≥3 steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).

    Time frame: Day 1 to Week 48

  3. Percentage of Patients Developing PDR

    Percentage of patients developing Proliferative Diabetic Retinopathy (PDR) from baseline through Week 48

    Time frame: Day 1 to Week 48

  4. Percentage of Patients Developing PDR or ASNV

    Percentage of patients developing Proliferative Diabetic Retinopathy (PDR) or Anterior segment neovascularization (ASNV) from baseline through Week 48

    Time frame: Day 1 to Week 48

  5. Percentage of Patients Developing Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR

    Percentage of patients developing vitreous hemorrhage or tractional retinal detachment believed to be due to Proliferative Diabetic Retinopathy (PDR) from baseline through Week 48

    Time frame: Day 1 to Week 48

  6. Percentage of Patients Developing DME

    Percentage of patients developing Diabetic Macular Edema (DME) from baseline through Week 48

    Time frame: Day 1 to Week 48

  7. Percentage of Patients With a ≥2-step or ≥3-step Worsening on DRSS

    Percentage of patients with a ≥2-step or ≥3-step worsening on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).

    Time frame: Day 1 to Week 48

  8. Percentage of Patients Who Lost ≥5, ≥10, or ≥15 Letters in BCVA

    Percentage of patients who lost ≥5, ≥10, or ≥15 letters in Best-corrected Visual Acuity (BCVA) from baseline by visit over time. Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.

    Time frame: Day 1 to Week 48

  9. Time to First Development of PDR, ASNV, or DME

    Time to first development of Proliferative Diabetic Retinopathy (PDR), Anterior segment neovascularization (ASNV), or Diabetic Macular Edema (DME) through Week 48

    Time frame: Day 1 to Week 48

  10. Time to First Development of PDR or ASNV

    Time to first development of Proliferative Diabetic Retinopathy (PDR) or Anterior segment neovascularization (ASNV) through Week 48

    Time frame: Day 1 to Week 48

  11. Time to First Development of Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR

    Time to first development of vitreous hemorrhage or tractional retinal detachment believed to be due to Proliferative Diabetic Retinopathy (PDR) through Week 48

    Time frame: Day 1 to Week 48

Other outcomes

  1. Time to First Development of DME

    Time to first development of Diabetic Macular Edema (DME) through Week 48

    Time frame: Day 1 to Week 48

  2. Mean Change in OCT CST

    Mean change in Optical Coherence Tomography (OCT) central subfield retinal thickness (CST) from baseline by visit over time

    Time frame: Day 1 to Week 48

  3. Mean Change in BCVA

    Mean change in Best-corrected Visual Acuity (BCVA) from baseline by visit over time. Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.

    Time frame: Day 1 to Week 48

07

Results

Posted Sep 5, 2024

Participant flow

Participants were recruited based on physician referral at 52 medical centers between September 2021 and August 2022. The first participant was enrolled on 07 September 2021 and the last on 25 August 2022.

Primary Study (Through Week 48)
Participant flow — Primary Study (Through Week 48)
MilestoneKSI-301 - Treatment Group ATreatment Group B
Started128125
Completed120115
Not completed810
Withdrew: Adverse event14
Withdrew: Non-compliance with study schedule01
Withdrew: Withdrawal by subject42
Withdrew: Lost to follow-up23
Withdrew: Participant relocated10
After Week 48
Participant flow — After Week 48
MilestoneKSI-301 - Treatment Group ATreatment Group B
Started120115
Completed00
Not completed120115
Withdrew: Adverse event10
Withdrew: Non-compliance with study schedule10
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up33
Withdrew: Sponsor request115111

Outcome measures

PrimaryPercentage of Patients Improving ≥2 Steps on DRSS

Percentage of patients improving ≥2 steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients Improving ≥2 Steps on DRSS
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Percentage of Patients Improving ≥2 Steps on DRSS522
Statistical analysis
  • KSI-301 - Treatment Group A vs Treatment Group B · Cochran-Mantel-Haenszel · p = <0.0001 · Difference of weighted percentages: 39.7 · 95.02% CI 31.3 to 48.1Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. The CI are based on the normal approximation to the binomial proportions.
SecondaryPercentage of Patients Developing Any Sight-Threatening Complication

Percentage of patients developing any of the following Sight-Threatening Complication: Proliferative Diabetic Retinopathy (PDR), Anterior segment neovascularization (ASNV), Vitreous hemorrhage or tractional retinal detachment believed to be due to PDR, or Diabetic Macular Edema (DME) from baseline through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients Developing Any Sight-Threatening Complication
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Percentage of Patients Developing Any Sight-Threatening Complication326
Statistical analysis
  • KSI-301 - Treatment Group A vs Treatment Group B · Cochran-Mantel-Haenszel · p = <0.0001 · Difference of weighted percentages: -18.7 · 95.02% CI -26.2 to -11.2Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. The CI are based on the normal approximation to the binomial proportions.
SecondaryPercentage of Patients Improving ≥3 Steps on DRSS

Percentage of patients improving ≥3 steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients Improving ≥3 Steps on DRSS
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Percentage of Patients Improving ≥3 Steps on DRSS70
Statistical analysis
  • KSI-301 - Treatment Group A vs Treatment Group B · Cochran-Mantel-Haenszel · p = 0.0058 · Difference of weighted percentages: 5.6 · 95.02% CI 1.6 to 9.5Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. The CI are based on the normal approximation to the binomial proportions.
SecondaryPercentage of Patients Developing PDR

Percentage of patients developing Proliferative Diabetic Retinopathy (PDR) from baseline through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients Developing PDR
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Percentage of Patients Developing PDR210
Statistical analysis
  • KSI-301 - Treatment Group A vs Treatment Group B · Cochran-Mantel-Haenszel · p = 0.0149 · Difference of weighted percentages: -6.5 · 95.02% CI -11.8 to -1.3Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. The CI are based on the normal approximation to the binomial proportions.
SecondaryPercentage of Patients Developing PDR or ASNV

Percentage of patients developing Proliferative Diabetic Retinopathy (PDR) or Anterior segment neovascularization (ASNV) from baseline through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients Developing PDR or ASNV
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Percentage of Patients Developing PDR or ASNV210
SecondaryPercentage of Patients Developing Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR

Percentage of patients developing vitreous hemorrhage or tractional retinal detachment believed to be due to Proliferative Diabetic Retinopathy (PDR) from baseline through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients Developing Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Percentage of Patients Developing Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR23
SecondaryPercentage of Patients Developing DME

Percentage of patients developing Diabetic Macular Edema (DME) from baseline through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients Developing DME
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Percentage of Patients Developing DME117
SecondaryPercentage of Patients With a ≥2-step or ≥3-step Worsening on DRSS

Percentage of patients with a ≥2-step or ≥3-step worsening on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients With a ≥2-step or ≥3-step Worsening on DRSS
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Patients with a ≥2-step worsening on DRSS15
Patients with a ≥3-step worsening on DRSS03
SecondaryPercentage of Patients Who Lost ≥5, ≥10, or ≥15 Letters in BCVA

Percentage of patients who lost ≥5, ≥10, or ≥15 letters in Best-corrected Visual Acuity (BCVA) from baseline by visit over time. Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.

Time frame:
Day 1 to Week 48
Reported as:
Count of participants · Participants
Percentage of Patients Who Lost ≥5, ≥10, or ≥15 Letters in BCVA
ParticipantsKSI-301 - Treatment Group ATreatment Group B
Participants who lost ≥ 5 letters from baseline to Week 8815
Participants who lost ≥ 5 letters from baseline to Week 201515
Participants who lost ≥ 5 letters from baseline to Week 321710
Participants who lost ≥ 5 letters from baseline to Week 44128
Participants who lost ≥ 5 letters from baseline to Week 481411
Participants who lost ≥ 10 letters from baseline to Week 823
Participants who lost ≥ 10 letters from baseline to Week 2024
Participants who lost ≥ 10 letters from baseline to Week 3251
Participants who lost ≥ 10 letters from baseline to Week 4442
Participants who lost ≥ 10 letters from baseline to Week 4851
Participants who lost ≥ 15 letters from baseline to Week 811
Participants who lost ≥ 15 letters from baseline to Week 2011
Participants who lost ≥ 15 letters from baseline to Week 3240
Participants who lost ≥ 15 letters from baseline to Week 4400
Participants who lost ≥ 15 letters from baseline to Week 4830
SecondaryTime to First Development of PDR, ASNV, or DME

Time to first development of Proliferative Diabetic Retinopathy (PDR), Anterior segment neovascularization (ASNV), or Diabetic Macular Edema (DME) through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Median · Months
Time to First Development of PDR, ASNV, or DME
MonthsKSI-301 - Treatment Group ATreatment Group B
Time to First Development of PDR, ASNV, or DMENA (NA to NA)NA (11.5 to NA)
SecondaryTime to First Development of PDR or ASNV

Time to first development of Proliferative Diabetic Retinopathy (PDR) or Anterior segment neovascularization (ASNV) through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Median · Months
Time to First Development of PDR or ASNV
MonthsKSI-301 - Treatment Group ATreatment Group B
Time to First Development of PDR or ASNVNA (NA to NA)NA (11.5 to NA)
SecondaryTime to First Development of Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR

Time to first development of vitreous hemorrhage or tractional retinal detachment believed to be due to Proliferative Diabetic Retinopathy (PDR) through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Median · Months
Time to First Development of Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR
MonthsKSI-301 - Treatment Group ATreatment Group B
Time to First Development of Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDRNA (NA to NA)NA (NA to NA)
Other pre-specifiedTime to First Development of DME

Time to first development of Diabetic Macular Edema (DME) through Week 48

Time frame:
Day 1 to Week 48
Reported as:
Median · Months
Time to First Development of DME
MonthsKSI-301 - Treatment Group ATreatment Group B
Time to First Development of DMENA (NA to NA)NA (NA to NA)
Other pre-specifiedMean Change in OCT CST

Mean change in Optical Coherence Tomography (OCT) central subfield retinal thickness (CST) from baseline by visit over time

Time frame:
Day 1 to Week 48
Reported as:
Mean · Microns
Mean Change in OCT CST
MicronsKSI-301 - Treatment Group ATreatment Group B
Week 8-9.8 ± 10.644.5 ± 17.22
Week 20-12.8 ± 13.426.6 ± 28.99
Week 32-13.9 ± 14.885.2 ± 27.86
Week 44-8.9 ± 19.71-0.5 ± 17.12
Week 48-15.2 ± 16.35-0.7 ± 15.76
Other pre-specifiedMean Change in BCVA

Mean change in Best-corrected Visual Acuity (BCVA) from baseline by visit over time. Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.

Time frame:
Day 1 to Week 48
Reported as:
Mean · ETDRS Letters
Mean Change in BCVA
ETDRS LettersKSI-301 - Treatment Group ATreatment Group B
Week 81.3 ± 5.020.2 ± 4.80
Week 201.1 ± 5.220.3 ± 6.29
Week 320.9 ± 8.681.2 ± 4.87
Week 441.0 ± 5.631.6 ± 5.55
Week 481.1 ± 6.441.5 ± 5.49

Adverse events

Collected over Adverse Events (AEs) reported through the End of Study or Early Termination (ET). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KSI-301 - Treatment Group A (Day 1 to Week 48)1/128 (0.8%)18/128 (14.1%)49/128 (38.3%)
Treatment Group B (Day 1 to Week 48)1/125 (0.8%)12/125 (9.6%)51/125 (40.8%)
KSI-301 - Treatment Group A (Post Week 48 to End of Study)1/120 (0.8%)8/120 (6.7%)15/120 (12.5%)
Treatment Group B (Post Week 48 to End of Study)0/115 (0%)3/115 (2.6%)9/115 (7.8%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventKSI-301 - Treatment Group A (Day 1 to Week 48)Treatment Group B (Day 1 to Week 48)KSI-301 - Treatment Group A (Post Week 48 to End of Study)Treatment Group B (Post Week 48 to End of Study)
Chest painGeneral disorders1/1280/1252/1200/115
OsteomyelitisInfections and infestations1/1282/1252/1200/115
Coronary artery diseaseCardiac disorders2/1280/1250/1200/115
Localised infectionInfections and infestations2/1280/1250/1200/115
Cerebrovascular accidentNervous system disorders0/1281/1250/1201/115
Diabetic footSkin and subcutaneous tissue disorders0/1281/1251/1201/115
Back painMusculoskeletal and connective tissue disorders0/1280/1250/1201/115
Skin ulcerSkin and subcutaneous tissue disorders0/1280/1250/1201/115
Diabetic ketoacidosisMetabolism and nutrition disorders1/1280/1251/1200/115
Osteomyelitis acuteInfections and infestations0/1280/1251/1200/115
Most frequent other events
Most frequent other events
EventKSI-301 - Treatment Group A (Day 1 to Week 48)Treatment Group B (Day 1 to Week 48)KSI-301 - Treatment Group A (Post Week 48 to End of Study)Treatment Group B (Post Week 48 to End of Study)
Diabetic retinal oedema - Study EyeEye disorders2/12818/1253/1203/115
Diabetes mellitusMetabolism and nutrition disorders15/1288/1253/1202/115
Cataract - Study EyeEye disorders13/1285/1253/1200/115
HypertensionVascular disorders12/12810/1252/1201/115
Conjunctival haemorrhage - Study EyeEye disorders9/1284/1251/1200/115
COVID-19Infections and infestations9/1286/1251/1200/115
Diabetic retinopathy - Study EyeEye disorders2/1288/1251/1203/115
Cataract - Fellow EyeEye disorders7/1283/1251/1200/115

Baseline characteristics

Full analysis set defined as all randomized subjects who received any study treatment (KSI-301 or sham) and have gradable DRSS value at baseline. Subjects will be analyzed according to their randomized treatment.

Age, Categorical
Age, Categorical(Participants)KSI-301 - Treatment Group ATreatment Group BTotal
<=18 years000
Between 18 and 65 years9695191
>=65 years323062
Age, Continuous
Age, Continuous(years)KSI-301 - Treatment Group ATreatment Group BTotal
Mean56.4 ± 11.3957 ± 9.6356.7 ± 10.54
Sex: Female, Male
Sex: Female, Male(Participants)KSI-301 - Treatment Group ATreatment Group BTotal
Female5156107
Male7769146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KSI-301 - Treatment Group ATreatment Group BTotal
Hispanic or Latino5752109
Not Hispanic or Latino7173144
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)KSI-301 - Treatment Group ATreatment Group BTotal
American Indian or Alaska Native022
Asian336
Native Hawaiian or Other Pacific Islander000
Black or African American132336
White10896204
More than one race202
Unknown or Not Reported213
Geographic Region
Geographic Region(Participants)KSI-301 - Treatment Group ATreatment Group BTotal
North America123120243
Rest of World5510
Diabetic Retinopathy Severity Scale (DRSS) at Baseline
Diabetic Retinopathy Severity Scale (DRSS) at Baseline(Participants)KSI-301 - Treatment Group ATreatment Group BTotal
DRSS Level ≤47464591
DRSS Level ≥538280162
08

Study locations

61 sites
  • Retinal Research Institute, LLC
    Phoenix, Arizona 85014, United States
  • Retina Vitreous Associates
    Beverly Hills, California 90211, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • Retinal Consultants Medical Group Inc
    Sacramento, California 95825, United States
  • California Retina Consultants - Santa Maria
    Santa Maria, California 93454, United States
  • Connecticut Eye Consultants
    Danbury, Connecticut 06810, United States
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
  • The Macula Center/ Blue Ocean Clinical Research
    Clearwater, Florida 33761, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Med Eye Associates
    Miami, Florida 33143, United States
  • Florida Retina Institute
    Orlando, Florida 32806, United States
  • Center for Retina & Macular Disease
    Winter Haven, Florida 33880, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Retina Specialists of Idaho
    Boise, Idaho 83713, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Springfield Clinic LLP
    Springfield, Illinois 62703, United States
  • Retina Associates PA
    Lenexa, Kansas 66215, United States
  • Cumberland Valley Retina Consultants PC
    Hagerstown, Maryland 21740, United States
  • Foundation for Vision Research
    Grand Rapids, Michigan 49525, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Envision Ocular LLC
    Bloomfield, New Jersey 07003, United States
  • Long Island Vitreoretinal Consultants
    Hauppauge, New York 11788, United States
  • Ophthalmic Consultants of Long Island
    Oceanside, New York 11572, United States
  • Graystone Eye
    Hickory, North Carolina 28603-2588, United States
  • Cascade Medical Research Institute
    Eugene, Oregon 97401, United States
  • MidAtlantic Retina
    Bethlehem, Pennsylvania 18017-9412, United States
  • Charleston Neurosciences Institute
    Beaufort, South Carolina 29902, United States
  • Charleston Neuroscience Center
    Charleston, South Carolina 29414, United States
  • Southeastern Retina Associates PC
    Knoxville, Tennessee 37909, United States
  • Charles Retina Institute
    Memphis, Tennessee 38119-4823, United States
  • Tennessee Retina PC
    Nashville, Tennessee 37203, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Panhandle Eye Group, LLP
    Amarillo, Texas 79106, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Retina Consultants of Texas (Houston)
    Bellaire, Texas 77401, United States
  • Star Vision Consultants
    Burleson, Texas 76028, United States
  • Retina Consultants of Texas (Katy)
    Katy, Texas 77494, United States
  • Texas Retina Associates
    Plano, Texas 75075, United States
  • Austin Retina Associates (Round Rock)
    Round Rock, Texas 78681, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retina Consultants of San Antonio
    San Antonio, Texas 78240, United States
  • Retina Consultants of Texas - (Woodlands)
    The Woodlands, Texas 77384, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Spokane Eye
    Spokane, Washington 99204, United States
  • OFTEX s.r.o.
    Pardubice, Pardubický Kraj 530 02, Czechia
  • Axon Clinical, s.r.o.
    Praha 5, 15 0 00, Czechia
  • Pauls Stradins Clinical University Hospital
    Riga, LV-1002, Latvia
  • Latvian American Eye Center
    Rīga, LV-1009, Latvia
  • Warszawski Szpital Okulistyczny
    Warszawa, Mazowieckie 01-258, Poland
  • Optimum Profesorskie Centrum Okulistyki
    Gdansk, Pomorskie 80-952, Poland
  • Oftalmika Sp. z o.o.
    Bydgoszcz, 85-631, Poland
  • Emanuelli Research & Development Center LLC
    Arecibo, 00612, Puerto Rico
  • Fakultna nemocnica s poliklinikou F. D. Roosevelta
    Banska Bystrica, 975 17, Slovakia
  • Fakultna nemocnica Trencin
    Trencin, 911 71, Slovakia
  • Hospital Universitario de Bellvitge
    L'hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitari General de Catalunya - Grupo Quironsalud
    Sant Cugat del Valles, Barcelona 08195, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Madrid, Majadanonda 28220, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50001, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50006, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Aug 2023, 22 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Oct 4, 2021
StartActual
Sep 7, 2021
Primary completionActual
Aug 3, 2023
CompletionActual
Aug 31, 2023
Results first posted
Sep 5, 2024
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05066230
Lead sponsor
Kodiak Sciences Inc
Responsible party
Sponsor
First posted
Oct 4, 2021
Start date
Sep 7, 2021
Primary completion
Aug 3, 2023
Completion
Aug 31, 2023
Results posted
Sep 5, 2024
Last update
Sep 5, 2024

Study contacts

Pablo Velazquez-Martin, MD
study director · Kodiak Sciences Inc
Daniel Janer, MD
study director · Kodiak Sciences Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tarcocimab tedromer

Start the discussion